{"filing":{"accession_number":"0001193125-26-279778","cik":"0001958777","ticker":"FBLG","company_name":"FibroBiologics, Inc.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"fblg-20260622.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526279778/fblg-20260622.htm"},"events":[{"id":13285,"run_id":11792,"accession_number":"0001193125-26-279778","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"FibroBiologics held its Annual Meeting on June 22, 2026, with stockholders voting on four proposals: election of Class III director Pete O'Heeron, ratification of WithumSmith+Brown, PC as independent auditor, approval of warrant issuance under Nasdaq Rule 5635(d), and approval of the 2026 Equity and Incentive Compensation Plan. All proposals passed with detailed vote tallies disclosed.","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10388,"accession_number":"0001193125-26-279778","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 discloses the final voting results from FibroBiologics' Annual Meeting held on June 22, 2026, covering four proposals: election of a Class III director (Pete O'Heeron), ratification of the independent auditor (WithumSmith+Brown, PC), approval of warrant issuance under Nasdaq Rule 5635(d), and approval of the 2026 Equity and Incentive Compensation Plan. The detailed vote tallies for each proposal are the core disclosure, making this a textbook shareholder vote results event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T21:16:55.363586+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":13286,"run_id":11792,"accession_number":"0001193125-26-279778","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Stockholders approved and adopted the FibroBiologics, Inc. 2026 Equity and Incentive Compensation Plan, which authorizes 2,061,968 shares and enables the Compensation Committee to grant equity-based and cash-based compensation to employees, officers, consultants, and directors, including performance-based awards and evergreen provisions.","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10387,"accession_number":"0001193125-26-279778","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on stockholder approval and adoption of the FibroBiologics, Inc. 2026 Equity and Incentive Compensation Plan, which enables the Compensation Committee to provide equity-based and cash-based compensation to employees, officers, consultants, and directors. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from executive departures or appointments. The plan's material features—including 2,061,968 available shares, evergreen provisions, and performance-based award mechanisms—directly affect executive and employee compensation structures and are material to investors assessing the company's capital allocation and incentive practices.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T21:16:55.363586+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10387,"accession_number":"0001193125-26-279778","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on stockholder approval and adoption of the FibroBiologics, Inc. 2026 Equity and Incentive Compensation Plan, which enables the Compensation Committee to provide equity-based and cash-based compensation to employees, officers, consultants, and directors. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from executive departures or appointments. The plan's material features—including 2,061,968 available shares, evergreen provisions, and performance-based award mechanisms—directly affect executive and employee compensation structures and are material to investors assessing the company's capital allocation and incentive practices.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T21:16:55.363586+00:00","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-06-23"},{"id":10388,"accession_number":"0001193125-26-279778","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 discloses the final voting results from FibroBiologics' Annual Meeting held on June 22, 2026, covering four proposals: election of a Class III director (Pete O'Heeron), ratification of the independent auditor (WithumSmith+Brown, PC), approval of warrant issuance under Nasdaq Rule 5635(d), and approval of the 2026 Equity and Incentive Compensation Plan. The detailed vote tallies for each proposal are the core disclosure, making this a textbook shareholder vote results event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T21:16:55.363586+00:00","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-06-23"}]}